Semaglutide denied as not FDA-approved for this use by Anthem?

Anthem's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Anthem Denied Semaglutide as "Not FDA-Approved" — and How to Respond

This denial from Anthem typically reflects one of three situations: (1) the specific semaglutide product or formulation prescribed is not the FDA-approved branded version (compounded semaglutide, for example, does not carry FDA approval); (2) the indication documented on the claim does not match any of the FDA-approved indications for the product prescribed; or (3) Anthem's system has not updated its records to reflect a newer FDA approval. Each scenario has a different appeal path.

## Why This Is Contestable

For FDA-approved branded semaglutide products used within their approved indications, the "not FDA-approved" denial code is a factual error that can be corrected with documentation. The FDA approval record is public and verifiable. If the denial is based on off-label use, the analysis is more nuanced — some plans cover off-label use when supported by recognized compendia, and the prescriber's letter should address this directly. If the product is compounded, coverage is genuinely more limited and the appeal should focus on medical necessity and lack of commercially available alternatives.

## Your Federal Appeal Rights

• ERISA §503 / ACA §2719 internal appeal: Request the specific basis for Anthem's not-FDA-approved determination — which product, which indication, and which policy provision. Submit within the deadline on your EOB.
• External review (ACA §2719): Available after the final internal denial, generally within four months. Independent reviewers assess FDA approval status objectively.
• Expedited review: Available when clinical urgency is present.

## What to Gather

1. The FDA-approved prescribing information (label) for the specific semaglutide product prescribed — available at FDA.gov. Confirm the product name, NDC, and approved indications. 2. Anthem's clinical or coverage policy for semaglutide — identify whether the denial is about the product itself or the indication. 3. The FDA product approval page or summary — attach as an exhibit if the denial rests on a factual error about approval status. 4. Prescriber's letter: For approved indications, the letter should confirm the product name, the FDA-approved indication being treated, and the clinical basis. For off-label use, the letter should cite the recognized compendium or guideline organization supporting the use. 5. Diagnosis confirmation and chart documentation — establishing that the documented indication matches an approved use.

## Criteria-Mapping Structure

For each element of Anthem's policy that triggered the denial, map your documentation to it: product name and FDA approval status; indication on claim versus approved indication in the label; prescriber's confirmation that use is within labeling. A one-page table with these three rows, each citing a specific exhibit, is often sufficient for an approval-status denial.

## Key Argument

FDA approval is a matter of public record. If the product is approved and the indication matches the label, the denial rests on a correctable factual error. Provide the documentation and request that Anthem's clinical reviewer re-adjudicate on the corrected record.